|
|
Mr. Takuro Wakabayashi has served TMS as CEO since 2018, and previously as co-CEO between 2011 and 2018. During his tenure at TMS, he led deals with Biogen and Ji-Xing (now CORXEL) and led the company’s initial public offering in 2022, which is the first global IPO by a Japan-based biotech company. Prior to TMS, Takuro was the founder and managing director of an incubator company dedicated to support startups to commercialize technologies, including biomedical discoveries, derived from academic institutions in Japan. Takuro earned an MBA from INSEAD and received his LLB from the University of Tokyo. |
|
|
Professor Emeritus at Tokyo University of Agriculture and Technology Dr. Keiji Hasumi is the scientific founder of TMS, served as co-CEO between 2011 and 2018, and currently serves as the Chief Scientific Officer. Keiji discovered a family of small molecule compounds produced by a black mold stachybotrys microspora, named SMTP (Stachybotrys Microspora Triprenyl Phenols), which includes TMS-007 and TMS-008. He brought TMS-007 from discovery stage to clinical proof-of-concept in humans. Keiji earned his Ph.D from Tokyo University of Agriculture and Technology, where he was a student and long-term colleague of Dr. Akira Endo who discovered and developed statins. Keiji has published over 150 peer-reviewed original articles. |
|
|
Dr. Noriaki Inamura has served in senior management positions in research and development of TMS since 2020, and currently serves as Executive Vice President of Development. He has a wealth of drug development experience in 40 years of his tenure at Fujisawa/Astellas, Sanofi and Seikagaku Cooperation, where he led R&D activities. Noriaki played key roles in discovery and development of global medicines including tacrolimus and micafungin. He received Drug Discovery Science Award from the Pharmaceutical Society of Japan for his work in tacrolimus in 1997. Noriaki graduated and received his Ph.D. from Kyoto University School, Faculty of Agriculture and Graduate School of Agriculture. |
|
|
Mr. Go Ito has been CFO of TMS since 2018. During his tenure at TMS, he led multiple private financing rounds and its IPO in 2022, the first global IPO as a Japan-based biotech company. Previously Go served a software company for 17 years where he led a merger exit with a system engineer services company. Prior to this, he was a consultant and provided strategic and financial advice for medical institutions Go received BS in economics from Tohoku University. |
